Q1 Earnings Forecast for Veracyte Issued By Leerink Partnrs

Veracyte, Inc. (NASDAQ:VCYT - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Veracyte in a research note issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings of $0.08 per share for the quarter, down from their previous forecast of $0.11. The consensus estimate for Veracyte's current full-year earnings is $0.68 per share. Leerink Partnrs also issued estimates for Veracyte's Q3 2025 earnings at $0.23 EPS.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The firm had revenue of $118.63 million for the quarter, compared to analysts' expectations of $110.73 million. During the same period in the prior year, the company posted ($0.39) earnings per share.

A number of other research analysts also recently commented on the company. Craig Hallum began coverage on Veracyte in a report on Thursday, March 20th. They set a "buy" rating and a $45.00 target price on the stock. Stephens restated an "overweight" rating and set a $45.00 price objective on shares of Veracyte in a research note on Wednesday, March 26th. StockNews.com downgraded shares of Veracyte from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. UBS Group increased their target price on shares of Veracyte from $46.00 to $49.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Finally, Guggenheim decreased their price target on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.60.

Veracyte Stock Performance

Shares of VCYT stock traded up $0.09 during trading hours on Thursday, hitting $32.23. 478,110 shares of the company were exchanged, compared to its average volume of 863,279. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -214.87 and a beta of 2.03. Veracyte has a one year low of $19.48 and a one year high of $47.32. The business's 50-day simple moving average is $32.25 and its two-hundred day simple moving average is $37.32.

Institutional Trading of Veracyte

Several hedge funds have recently bought and sold shares of VCYT. Vanguard Group Inc. increased its stake in shares of Veracyte by 6.0% in the fourth quarter. Vanguard Group Inc. now owns 8,211,612 shares of the biotechnology company's stock valued at $325,180,000 after purchasing an additional 463,098 shares during the period. Artisan Partners Limited Partnership increased its position in Veracyte by 31.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 6,599,264 shares of the biotechnology company's stock valued at $261,331,000 after acquiring an additional 1,576,432 shares during the period. ArrowMark Colorado Holdings LLC increased its position in Veracyte by 3.3% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 3,080,027 shares of the biotechnology company's stock valued at $121,969,000 after acquiring an additional 97,824 shares during the period. Nuveen Asset Management LLC raised its stake in Veracyte by 0.7% during the 4th quarter. Nuveen Asset Management LLC now owns 1,194,392 shares of the biotechnology company's stock valued at $47,298,000 after acquiring an additional 8,797 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its position in Veracyte by 226.8% during the 4th quarter. Driehaus Capital Management LLC now owns 1,183,766 shares of the biotechnology company's stock worth $46,877,000 after acquiring an additional 821,554 shares during the period.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.